Item 8.01. Other Events.



On September 13, 2021, BeiGene, Ltd. ("BeiGene") announced that the U.S. Food
and Drug Administration (FDA) accepted for review a Biologics License
Application (BLA) for its anti-PD-1 antibody tislelizumab as a treatment for
patients with unresectable recurrent locally advanced or metastatic esophageal
squamous cell carcinoma (ESCC) after prior systemic therapy. The Prescription
Drug User Fee Act (PDUFA) target action date is July 12, 2022. The full text of
this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated herein by reference.

On September 15, 2021, BeiGene announced that BRUKINSA® (zanubrutinib) has
received accelerated approval from the U.S. Food and Drug Administration (FDA)
for the treatment of adult patients with relapsed or refractory (R/R) marginal
zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. The
full text of this press release is filed as Exhibit 99.2 to this Current Report
on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Press Release titled "BeiGene Announces U.S. FDA

Acceptance of Biologics


                          License Application for Tislelizumab in

Esophageal Squamous Cell Carcinoma",


                          issued by BeiGene, Ltd. on September 13, 2021.

       99.2               Press Release titled "U.S. FDA Grants BRUKINSA®

(Zanubrutinib) Accelerated


                          Approval in Relapsed or Refractory Marginal Zone Lymphoma", issued by
                          BeiGene, Ltd. on September 15, 2021.

       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------



                                 Exhibit Index

   Exhibit No.            Description

       99.1                 P    ress Release titled "BeiGene Announces

U.S. FDA Acceptance of Biologics


                          License Application for Tislelizumab in

Esophageal Squamous Cell Carcinoma",


                          issued by BeiGene, Ltd. on September 13, 2021.

                            Press Release titled "U.S. FDA Grants BRUKINSA    ®     (Zanubrutinib)
                          Accelerated Approval in Relapsed or Refractory

Marginal Zone Lymphoma ",


                          issued by BeiGene, Ltd. on September 15, 2021.

       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses